November 12, 2026 · Gynecologic oncology · DOI: 10.1016/j.ygyno.2026.10.032

Translational science in modern gynecologic oncology trials.

Listen to this summary

This review provides an operational framework for building translational science into gynecologic oncology trials from the start, rather than planning biomarker endpoints late. The authors define exploratory, integrated, and integral biomarker tiers linked to analytical validation, clinical validation, and level of evidence, and propose minimum standards for tissue and blood specimen collection, handling, clinical annotation, and reporting (BRISQ, SPREC, BloodPAC). It also addresses how ctDNA and emerging platforms should be used and argues that discovery findings should not be treated as validated biomarkers.

Rebecca C Arend, Dhruva Dave, Casey M Cosgrove, Elise Kohn, Fiona Simpkins, Sarah F Adams, Dimitrios Nasioudis, Anil K Sood

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play